سعر تيبزول Tibezole‏ 125 مجم 10 اقراص 2026

Ornidazole 125 mg tablets (Pharopharma, Egypt), nitroimidazole antiprotozoal.

• Reported: peripheral neuropathy (rare); transient haematological changes (leucopenia, agranulocytosis, aplastic anaemia, thrombocytopenia) and anaphylactic shock (very rare); vaginal Candida superinfection, mood disorders, ataxia and vertigo (frequency not known).General active-ingredient information · AFMPS / FAGG (Belgian Federal Agency for Medicines and Health Products)

• Hypersensitivity to nitroimidazoles or to any of the excipients.General active-ingredient information · AFMPS / FAGG (Belgian Federal Agency for Medicines and Health Products)

• High-dose and/or prolonged treatment (>10 days): regular clinical and laboratory tests, notably liver function tests, are recommended; regular blood counts (leucocyte formula) are advised with a history of blood disorders.General active-ingredient information · AFMPS / FAGG (Belgian Federal Agency for Medicines and Health Products)
• Stop treatment if ataxia, vertigo or mental confusion occur; ornidazole may aggravate existing candidiasis. It can markedly impair the ability to drive or use machines.General active-ingredient information · AFMPS / FAGG (Belgian Federal Agency for Medicines and Health Products)

• AlcoholAvoid alcoholic drinks and alcohol-containing medicines: disulfiram-like reaction (warmth, flushing, vomiting, tachycardia).AFMPS / FAGG (Belgian Federal Agency for Medicines and Health Products)
• Oral anticoagulants (e.g. warfarin)Anticoagulant effect may be increased (chemical relationship with metronidazole); closer INR monitoring is recommended.AFMPS / FAGG (Belgian Federal Agency for Medicines and Health Products)

• No or limited human data; animal studies showed no direct or indirect harmful reproductive effects. As a precaution, avoid use in the first trimester.General active-ingredient information · AFMPS / FAGG (Belgian Federal Agency for Medicines and Health Products)
• Insufficient data on excretion in breast milk; a risk to the infant cannot be excluded. Should not be used during breastfeeding.General active-ingredient information · AFMPS / FAGG (Belgian Federal Agency for Medicines and Health Products)

• Liver function tests and leucocyte counts during high-dose or prolonged (>10 days) therapy.General active-ingredient information · AFMPS / FAGG (Belgian Federal Agency for Medicines and Health Products)